Weight Loss Investigational 🔥 Trending

CagriSema

A Novo Nordisk investigational combination of cagrilintide and semaglutide, designed to pair amylin and GLP-1 pathways in obesity.

CagrilintideSemaglutideAmylinGLP-1ObesityNovo Nordisk

Also appears in: Hormone

Status
Investigational

This compound has a genuine development or study trail, but it is not an approved routine drug.

Category
Weight Loss

Primary lane: Weight Loss. Also surfaces under Hormone for browsing and discovery.

Aliases
0

No major aliases are tracked for this profile yet.

Signal depth
Medium

No FDA label signal · 30 trials · 44 PubMed results

Promising
Research evidence

CagriSema has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

CagriSema has 27 name-matched clinical trials (highest phase: Phase 3) and 44 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet.

Human data
Phase 3
Trial quality
Large RCT
Outcomes
Clinical outcomes
Replication
Meta-analysis
Literature
Established
PHASE3 · Randomized REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels PHASE3 · Randomized A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight PHASE3 · Randomized A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor The Lancet · 15 citations CagriSema and the link between obesity and type 2 diabetes Indian Journal of Endocrinology and Metabolism · 14 citations Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis Nature Metabolism · 9 citations CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What CagriSema is

CagriSema is Novo Nordisk’s investigational obesity combination that pairs cagrilintide with semaglutide.

Why it matters

It is one of the highest-profile examples of the industry trying to combine amylin and GLP-1 biology in a single branded program rather than selling the components as separate ideas.

Regulatory context

CagriSema is not FDA approved. It remains a late-stage investigational obesity drug program.

Practical reading note

CagriSema matters because it helps connect the standalone peptide pages to the combination products that people actually end up hearing about in headlines and social media.